• Explore /
  • Poster
  • / Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.

Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.

Abstract Poster

Authors

null

Charles S. Fuchs

Dana-Farber Cancer Institute, Boston, MA

Charles S. Fuchs , Andrew E. Denker , Josep Tabernero , Eric Van Cutsem , Atsushi Ohtsu , Baohoang Lam , Minori Koshiji , Yung-Jue Bang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02335411

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS184)

DOI

10.1200/jco.2016.34.4_suppl.tps184

Abstract #

TPS184

Poster Bd #

O10

Abstract Disclosures

Similar Posters

First Author: Charles S. Fuchs

First Author: Timothy Jay Price

First Author: A. Dimitrios Dimitrios Colevas

First Author: Farshid Dayyani